Interactions on record — worth a quick check against your medications. Based on 4 of 9 ingredients. Check your meds →
Dietary supplement

Kyo-Dophilus 9 Ingredients & Drug Interactions

by Kyo-Dophilus

Kyo-Dophilus 9 label
See full label image
Capsule Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
Clinical methodology reviewed by · Updated Sep 9, 2026 · Label data from the NIH DSLD
What is this page for?

First and foremost: checking Kyo-Dophilus 9 against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.

Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy

The interaction bottom line Most serious interaction: Moderate

Kyo-Dophilus 9 is a dietary supplement by Kyo-Dophilus with 9 active ingredients. Its ingredients are commonly taken for digestive health and regularity, diarrhea (including antibiotic-related), irritable bowel syndrome (ibs) symptoms.Based on those ingredients, 182 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are B. bifidum, B. breve, L. gasseri B. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

Jump to a section

Check Your Meds Against Kyo-Dophilus 9 by Kyo-Dophilus

Ask about any prescription or over-the-counter medication and we check it for interactions with Kyo-Dophilus 9 by Kyo-Dophilus — and tell you which ingredient is responsible.

Pharmacist-reviewed data Checks every ingredient Answer in seconds
Prefer a human? Send your question to our licensed pharmacists — free, answered by email within 24 hours.

HelloPharmacist Scorecard of Kyo-Dophilus 9 by Kyo-Dophilus

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

Generated from HelloPharmacist’s pharmacist-curated databases and editorial rules · Last generated Jul 11, 2026

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 9 active ingredients.
  • “Proprietary Probiotic Blend” is a proprietary blend — the label doesn't break down how much of each component you get.

Kyo-Dophilus 9 contains 9 probiotic strains: Lactobacillus rhamnosus, Bifidobacterium infantis, B. lactis, B. bifidum, B. breve, Lactobacillus gasseri (two different strains), and Bifidobacterium longum (two different strains). These are live beneficial bacteria meant to support your gut microbiome.

The capsule also contains gelatin, starch, and silica as inactive ingredients—fillers and binders that help hold the capsule together.

Does it work?

Not established
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not established

The graded evidence we hold for these ingredients covers different conditions than the ones this product is marketed for, so there's no established rating for its stated use.

Why this rating?
  • The label markets this product for: maintain balanced intestinal flora and immune function.
  • We looked for evidence on: Abdominal pain, Antibiotic-associated diarrhea, Asthma, Atopic dermatitis (eczema), Atopic disease, Bacterial vaginosis — and 4 related terms.
  • The closest evidence on file: Bifidobacterium Breve is rated "Insufficient Reliable Evidence To Rate" for Antibiotic-associated diarrhea (Natural Medicines).
  • Also on file: Bifidobacterium Breve is rated "Insufficient Reliable Evidence To Rate" for Asthma, Atopic disease, Atopic dermatitis (eczema), Clostridioides difficile infection, and more.

The evidence for Kyo-Dophilus 9 is mixed and incomplete. B. bifidum and B. breve show possibly effective ratings for a couple of conditions—B. bifidum for irritable bowel syndrome (IBS) and respiratory tract infections—but most uses listed lack reliable data.

For the other strains and conditions in our data, evidence is rated insufficient to say whether they work. That doesn't mean they don't; it means large, well-designed studies haven't confirmed benefit yet.

Talk with your pharmacist about what you're hoping this probiotic will do for you, and whether the evidence supports that use.

The evidence, ingredient by ingredient Bifidobacterium Bifidum Bifidobacterium Breve Lactobacillus Gasseri Bifidobacterium Longum

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 4 of the 4 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 4 of 4.
  • General safety write-ups exist for 4 of 4.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Kyo-Dophilus 9 is generally well tolerated in healthy people. Bloating and flatulence are common with probiotics in general, though these side effects haven't specifically been reported from all the strains in this blend.

Rare gastrointestinal side effects—abdominal discomfort, constipation, and distension—have been reported with some strains. Very rarely, a dry cough has occurred.

Be cautious if you have a weakened immune system or are critically ill; there have been rare cases of bacterial bloodstream infections (bacteremia) or sepsis from probiotic bacteria in severely compromised patients, though these cases are uncommon. Limited safety data exist during pregnancy and breastfeeding—the facts note B. longum is rated possibly safe, but data on the other strains aren't on file here.

Talk with your doctor or pharmacist before use if you're pregnant, breastfeeding, or have a weakened immune system.

Side effects, ingredient by ingredient Bifidobacterium Bifidum Bifidobacterium Breve Lactobacillus Gasseri Bifidobacterium Longum

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 4 of the 4 matched ingredients can interact with medications — Bifidobacterium Breve, Bifidobacterium Bifidum, Bifidobacterium Longum, Lactobacillus Gasseri.
  • The most serious interaction on file is rated Moderate.
  • For scale: 182 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

If you take any antibiotic drugs (antibacterial medications), separate them from this probiotic by several hours or consult your pharmacist on timing. The live organisms in Kyo-Dophilus 9 can be killed off if antibiotics are taken at the same time, reducing the probiotic's effectiveness.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with no established evidence rating for its marketed use. Moderate medication interactions have been identified, and safety information is well characterized.

Kyo-Dophilus 9 is a multi-strain probiotic that's generally well tolerated in healthy adults. Its main interaction is with antibiotics—don't take them at the same time; space doses apart instead.

If you're seriously ill, immunocompromised, or pregnant or breastfeeding, check with your doctor or pharmacist first. Use the drug checker to verify your specific medications before you start.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 6 of 9 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Sep 24, 2019.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Kyo-Dophilus 9, straight from the product label.

Brand Kyo-Dophilus
Barcode (UPC) 023542610421
Net contents 180 Capsule(s)
Market status On market
Date entered into DSLD Sep 24, 2019
DSLD ID 205166
Product type Non-nutrient/non-botanical
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Children (All), Infants/Baby (0 - 1 Year), Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Kyo-Dophilus 9 by Kyo-Dophilus, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
UPC/BARCODE
023542610421
IngredientAmount% DV
L. rhamnosus0 NP--
B. infantis0 NP--
B. lactis0 NP--
B. bifidum0 NP--
B. breve0 NP--
L. gasseri B0 NP--
L. gasseri M0 NP--
B. longum M0 NP--
Proprietary Probiotic Blend0 NP--
B. longum B0 NP--

Other ingredients: Gelatin, Starch, Silica

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formula

Kyo-Dophilus 9 is formulated with three lactobacillus strains and six bifidobacterium strains. This unique blend of nine probiotics contains specially cultured human strains of friendly bacteria that are carefully processed to retain viability at room temperature, insuring an adequate number of cells for colonization in the intestines.

A blend of nine probiotics

May contain trace amounts of fish.

General Statements

Kyo-Dophilus 9 helps maintain a balanced intestinal flora and promote healthy intestinal and immune function.

Promotes healthy intestinal function

Intestinal balance & immune support

Suggested/Recommended/Usage/Directions

Take Kyo-Dophilus 9 daily!

Suggested use: Take one capsule for adults (1/2 capsule for children under four) with a meal twice daily. For infants, sprinkle 1/2 capsule in food or juice.

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Precautions

Tamper resistant cap and seal: Do not use if cap drop ring or inner seal is broken or missing.

May contain trace amounts of fish.

Keep out of reach of children.

Seals/Symbols

GMP Certified

FDA Statement of Identity

Probiotic Supplement

Formulation

Free of: sodium, dairy, soy, preservatives, artificial colors or flavors.

Storage

Store in a cool, dry place with cap tight.

Refrigeration not required.

Is this label outdated? Report a formula or label change and our pharmacy team will review it.

See for yourself

Kyo-Dophilus 9 by Kyo-Dophilus label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

Kyo-Dophilus 9 label

Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.

View the full label (PDF)
What’s inside

The Ingredients in Kyo-Dophilus 9 by Kyo-Dophilus

These are the 9 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Proprietary Probiotic Blend

0 NP per serving

Other (inactive) ingredients: Gelatin, Starch, Silica. These complete the product’s ingredient list but are not active constituents.

Interaction report

Kyo-Dophilus 9 by Kyo-Dophilus Drug Interactions

Want to check YOUR meds against Kyo-Dophilus 9?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

 Go to the checker
182Drugs
182 Moderate

Ingredients driving the most interactions

B. bifidum 182
B. breve 182
L. gasseri B 182
B. longum M 182

Individual Drug Interactions

The ingredients in Kyo-Dophilus 9 interact with 182 drugs. Click any drug to see the details.

4 of the 9 ingredients in Kyo-Dophilus 9 interact with drugs. Each result below shows which ingredient is responsible. B. bifidum B. breve L. gasseri B B. longum M

Each ingredient & the kinds of drugs it affects

For each ingredient in Kyo-Dophilus 9 with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

B. bifidum1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium. bifidum with antibiotic drugs might decrease the effectiveness of B. bifidum.
Since B. bifidum preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. bifidum preparations by at least 2 hours.

Likelihood Probable Evidence D
B. bifidum full monograph & interactions

B. breve1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium breve with antibiotic drugs might decrease the effectiveness of B. breve.
Since B. breve preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. breve preparations by at least 2 hours.

Likelihood Probable Evidence D
B. breve full monograph & interactions

L. gasseri B1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lactobacillus gasseri with antibiotic drugs might decrease the effectiveness of L. gasseri.
Lactobacillus gasseri preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. gasseri preparations by at least two hours.

Likelihood Probable Evidence D
L. gasseri B full monograph & interactions

B. longum M1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium longum with antibiotic drugs might decrease the effectiveness of B. longum.
Since B. longum preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. longum preparations by at least 2 hours.

Likelihood Probable Evidence D
B. longum M full monograph & interactions
The maker

Brand information

Manufacturer and brand details for Kyo-Dophilus 9, from the product label.

Kyo-Dophilus

See all Kyo-Dophilus products
Name
Wakunaga of America Co., Ltd.
Street Address
23501 Madero
City
Mission Viejo
State
CA
ZipCode
92691
Web Address
www.kyolic.com
Pharmacist Counseling Corner

Kyo-Dophilus 9 by Kyo-Dophilus: Common Questions

Does Kyo-Dophilus 9 by Kyo-Dophilus interact with any medications?
Yes. Based on its ingredients, Kyo-Dophilus 9 has a known interaction with 182 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Kyo-Dophilus 9 contains 9 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take Kyo-Dophilus 9 while I'm on an antibiotic?
You can, but timing matters. Antibiotics can kill the live bacteria in the probiotic. Space them out—take your antibiotic at one time of day and the probiotic several hours later, or ask your pharmacist for the best schedule for your specific antibiotic. Don't skip either one.
Is Kyo-Dophilus 9 safe if I'm pregnant or breastfeeding?
We have limited safety data. One strain (B. longum) is rated possibly safe in pregnancy, but we don't have pregnancy or breastfeeding information on file for the other strains. Talk with your doctor or pharmacist before using it.
What if I have a weak immune system—should I take this?
Not without talking to your doctor first. The facts note that people with weakened immune systems should be cautious because there's a small risk of rare infections from the live bacteria. Your doctor can help you decide if it's right for you.
Will Kyo-Dophilus 9 help my IBS or hay fever?
For IBS, one strain (B. bifidum) is rated possibly effective, so there's some promise. For hay fever (allergic rhinitis), the evidence is insufficient—we don't have enough data to know either way. Your pharmacist can discuss whether it might be worth trying for your situation.
What side effects should I expect?
Bloating and gas are common with probiotics, though they're not specifically documented for all strains here. Rare side effects include abdominal discomfort, constipation, and distension. A dry cough has been reported once. Most people tolerate probiotics well.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Kyo-Dophilus 9 is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Kyo-Dophilus 9 label
Go deeper

The Full Monographs Behind Kyo-Dophilus 9’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Bifidobacterium Bifidum

Interacts with 182 drugs

Bifidobacterium bifidum is a 'friendly' bacteria (probiotic) that naturally lives in the human gut and is taken to support digestion and gut balance. Some evidence suggests probiotics may he...

Read the full Bifidobacterium Bifidum monograph → Herb & supplement monograph

Bifidobacterium Breve

Interacts with 182 drugs

Bifidobacterium breve is a 'friendly' gut bacterium taken as a probiotic, most often to support digestion and balance the gut microbiome. Some studies suggest possible benefits for certain d...

Read the full Bifidobacterium Breve monograph → Herb & supplement monograph

Lactobacillus Gasseri

Interacts with 182 drugs

Lactobacillus gasseri is a 'friendly' probiotic bacterium found naturally in the human gut, mouth, and vaginal tract, and in some fermented foods. Early research suggests it may help with di...

Read the full Lactobacillus Gasseri monograph → Herb & supplement monograph

Bifidobacterium Longum

Interacts with 182 drugs

Bifidobacterium longum is a 'friendly' bacterium found naturally in the human gut and used as a probiotic. It is generally well tolerated and is most studied for digestive issues, though evi...

Read the full Bifidobacterium Longum monograph →
Sources

Sources & How We Checked

Kyo-Dophilus 9's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 49 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Bifidobacterium Bifidum 7 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682-7. PubMed
  4. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  5. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  6. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  7. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed

See these in context on the Bifidobacterium Bifidum monograph →

Bifidobacterium Breve 9 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  4. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr. 2010;156(4):679-81. PubMed
  5. Sakurai Y, Watanabe T, Miura Y, et al. Clinical and bacteriologic characteristics of six cases of Bifidobacterium breve bacteremia due to probiotic administration in the neonatal intensive care unit. Pediatr Infect Dis J 2022;41(1):62-65. PubMed
  6. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  7. Wakabayashi Y, Nakayama S, Yamamoto A, et al. First case of necrotizing fasciitis and bacteremia caused by Bifidobacteriumbreve. Anaerobe 2022;76:102613.
  8. Takeda Y, Ota K, Kondo A, et al. A case of necrotizing fasciitis caused by Bifidobacterium breve. IDCases 2022;31:e01667. PubMed
  9. Suwantarat N, Romagnoli M, Wakefield T, Carroll KC. Ventriculoperitoneal shunt infection caused by Bifidobacterium breve. Anaerobe 2014;28:1-3. PubMed

See these in context on the Bifidobacterium Breve monograph →

Lactobacillus Gasseri 12 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Ramachandran L, Dontaraju VS, Patel K. Lactobacillus-associated spontaneous bacterial peritonitis in a liver cirrhosis patient on probiotics. Cureus. 2020;12(12):e11896. PubMed
  3. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  4. Ranchal P, Gupta R, Goldberg R, A Lobo S, Pascual A, El Khoury MY. Penicillin-sensitive Lactobacillus jensenii bacteremia. Am J Ther 2021;28(2):e250-e252. PubMed
  5. Grazioli-Gauthier L, Rigamonti E, Leo LA, Martinetti Lucchini G, Lo Priore E, Bernasconi E. Lactobacillus jensenii mitral valve endocarditis: Case report, literature review and new perspectives. IDCases 2022;27:e01401. PubMed
  6. Toprak NU, Bozan T, Yilmaz S, Buyukbayrak EE, Tigen ET. Polymicrobial bacteremia due to Lactobacillus jensenii and Veillonella montpellierensis in a pregnant patient; case report and review of literature. Anaerobe 2022;75:102576. PubMed
  7. Chazan B, Raz R, Shental Y, Sprecher H, Colodner R. Bacteremia and pyelonephritis caused by Lactobacillus jensenii in a patient with urolithiasis. Isr Med Assoc J 2008;10(2):164-5.
  8. Ramos-Coria D, Canto-Losa J, Carrillo-Vázquez D, Carbajal-Morelos L, Estrada-León R, Corona-Rodarte E. Lactobacillus gasseri liver abscess and bacteremia: a case report. BMC Infect Dis 2021;21(1):518. PubMed
  9. Elikowski W, Malek-Elikowska M, Lisiecka M, Bodora A, Wisniewska K, Oko-Sarnowska Z. Lactobacillus gasseri endocarditis on the aortic valve bioprosthesis - a case report. Pol Merkur Lekarski 2017;43(257):220-223.
  10. Esquibel A, Dababneh AS, Palraj BR. Lactobacillus gasseri causing bilateral empyema. Case Rep Infect Dis 2017;2017:4895619.
  11. Tleyjeh IM, Routh J, Qutub MO, Lischer G, Liang KV, Baddour LM. Lactobacillus gasseri causing Fournier's gangrene. Scand J Infect Dis 2004;36(6-7):501-3. PubMed
  12. Dickgiesser U, Weiss N, Fritsche D. Lactobacillus gasseri as the cause of septic urinary infection. Infection 1984;12(1):14-6. PubMed

See these in context on the Lactobacillus Gasseri monograph →

Bifidobacterium Longum 21 references
  1. Ha GY, Yang CH, Kim H, Chong Y. Case of sepsis caused by Bifidobacterium longum. J Clin Microbiol 1999;37:1227-8.
  2. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  3. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  4. Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. J Allergy Clin Immunol. 2012;130(6):1355-60. PubMed
  5. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  6. Pellonperä O, Vahlberg T, Mokkala K, et al. Weight gain and body composition during pregnancy: a randomised pilot trial with probiotics and/or fish oil. Br J Nutr. 2020 Nov 4:1-11. PubMed
  7. Pellonperä O, Mokkala K, Houttu N, et al. Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an at-risk group of overweight and obese women: A randomized, placebo-controlled, double-blind clinical trial PubMed
  8. Shahriari A, Karimi E, Shahriari M, Aslani N, Khooshideh M, Arab A. The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial PubMed
  9. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  10. Enomoto T, Sowa M, Nishimori K, et al. Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. Allergol Int 2014;63(4):575-85. PubMed
  11. US Food and Drug Administration (FDA). Dear Healthcare Provider Letter: Warning Regarding Use of Probiotics in Preterm Infants. September 2023. Available at: https://www.fda.gov/media/172606/download?attachment. Accessed November 1, 2023.
  12. Pillai A, Tan J, Paquette V, Panczuk J. Does probiotic bacteremia in premature infants impact clinically relevant outcomes? A case report and updated review of literature. Clin Nutr ESPEN. 2020;39:255-259. PubMed
  13. Sabaté JM, Iglicki F. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol 2022;28(7):732-744.
  14. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;52(11) PubMed
  15. Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 2015;107(1):56-9.
  16. Tamaki H, Nakase H, Inoue S, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc 2016;28(1):67-74.
  17. Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 2015;60(6):924-7. PubMed
  18. Esaiassen E, Cavanagh P, Hjerde E, Simonsen GS, Støen R, Klingenberg C. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis 2016;22(9):1664-6.
  19. Tena D, Losa C, Medina MJ, Sáez-Nieto JA. Peritonitis caused by Bifidobacterium longum: case report and literature review. Anaerobe 2014;27:27-30. PubMed
  20. Sangkanjanavanich S, Pradubpongsa P, Mitthamsiri W, Sangasapaviliya A, Boonpiyathad T. Bifidobacterium infantis 35624 efficacy in patients with uncontrolled asthma: A randomized placebo-controlled trial. Ann Allergy Asthma Immunol 2022;129(6):790-792. PubMed
  21. Wilson HL, Ong CW. Bifidobacterium longum vertebrodiscitis in a patient with cirrhosis and prostate cancer. Anaerobe 2017;47:47-50. PubMed

See these in context on the Bifidobacterium Longum monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring
Supplement interaction checker › Check any supplement or product against your medications Drug–drug interactions › Check two or more of your medications against each other Browse medications A–Z › Every drug we've checked against herbs & supplements NDC & pricing lookup › Find a drug’s NDCs, packaging and costs Ask a pharmacist › Free, personal answer from our licensed team